Gemcitabine Plus Docetaxel, Dacarbazine, Doxorubicin Combinations, or Doxorubicin Alone as First-Line Treatment for Advanced/Metastatic Leiomyosarcoma: A Retrospective Analysis at a Sarcoma Center
These findings reaffirm the efficacy of doxorubicin-based combination regimens as a first-line treatment for locally advanced and metastatic LMS, particularly in non-uterine LMS.
Authors
- Nam Q. Bui (ORCID: https://orcid.org/0000-0001-6896-4349)
- Ted Kim (ORCID: https://orcid.org/0000-0001-5470-0895)
- Kristen N. Ganjoo (ORCID: https://orcid.org/0000-0003-0452-9967)
- Minggui Pan (ORCID: https://orcid.org/0000-0002-8368-6524)
- Clara Hao
Institutions
- Stanford University (US)
Publication Details
- Journal
- Diseases
- Published
- 2025-03-11
- DOI
- https://doi.org/10.3390/diseases13030079
- Citations
- 2
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04